RET and medullary thyroid gland carcinoma: In patients naïve to other therapies, the ORR was 82.6% and 95.8% among those with RET fusion-positive NSCLC and TC, respectively, while in patients with RET-mutated MTC naïve to cabozantinib and/or vandetanib, it was 84.5% [8,9].